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Abstract 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyses one of the two steps in 
glycolysis which generate the reduced coenzyme NADH.  This reaction precedes the two 
ATP generating steps.  Thus, inhibition of GAPDH will lead to substantially reduced energy 
generation.  Consequently, there has been considerable interest in developing GAPDH 
inhibitors as anti-cancer and anti-parasitic agents.  Here, we describe the biochemical 
characterisation of GAPDH from the common liver fluke Fasciola hepatica (FhGAPDH).  
The primary sequence of FhGAPDH is similar to that from other trematodes and the 
predicted structure shows high similarity to those from other animals including the 
mammalian hosts.  FhGAPDH lacks a binding pocket which has been exploited in the design 
of novel antitrypanosomal compounds.  The protein can be expressed in, and purified from 
Escherichia coli; the recombinant protein was active and showed no cooperativity towards 
glyceraldehyde 3-phosphate as a substrate.  In the absence of ligands, FhGAPDH was a 
mixture of homodimers and tetramers, as judged by protein-protein crosslinking and 
analytical gel filtration.  The addition of either NAD
+
 or glyceraldehyde 3-phosphate shifted 
this equilibrium towards a compact dimer.  Thermal scanning fluorimetry demonstrated that 
this form was considerably more stable than the unliganded one.  These responses to ligand 
binding differ from those seen in mammalian enzymes.  These differences could be exploited 
in the discovery of reagents which selectively disrupt the function of FhGAPDH. 
 
Keywords:  glycolytic enzyme; trematode; drug target; vaccine target; neglected tropical 
disease; G3PDH 
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1. Introduction 
In recent years, there has been renewed interest in targeting metabolic enzymes in the 
treatment of infectious diseases [1].  This presents considerable challenges – most 
significantly the highly conserved nature of these enzymes which makes the discovery of 
reagents which discriminate between host and pathogen enzymes difficult.  However, the 
essential nature of pathways such as glycolysis mean that inhibition is likely to lead to growth 
inhibition and subsequent death of the pathogen.  Thus, increased efforts are being made to 
characterise the biochemistry of metabolic enzymes from pathogens with the long term aim 
of investigating their potential as drug targets.  A key goal of these studies is to identify 
biochemical differences between the pathogen enzyme and the host enzyme.  These 
differences may then provide the basis for the discovery of compounds which selectively 
disrupt the activity of the pathogen enzyme. 
 
Fasciola hepatica (the common liver fluke) is a trematode which infects humans and other 
mammals.  It is estimated that approximately 7 million humans are infected with millions 
more at risk; the majority of these people live in the developing world and fascioliasis is 
classified as a neglected tropical disease by WHO [2].  In addition, the organism causes a 
significant economic burden to agriculture globally since it infects domestic herbivores such 
as cows and sheep.  Over ten years ago global losses due to infection were estimated to be 
several billion US dollars [3].  F. hepatica infections can be treated with the modified 
benzimidazole drug triclabendazole.  This compound is highly effective and kills both mature 
and juvenile worms.  However, resistance to this drug is emerging worldwide and resistance 
to alternative benzimidazoles such as albendazole has also been reported [4-6].  It is 
inevitable that triclabendazole resistance will spread and the agricultural burden of F. 
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hepatica infections is likely to increase if the trend to warmer, wetter summers in temperate 
regions continues [7;8]. 
 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12) is a key enzyme in the 
glycolytic pathway.  It catalyses the oxidation of glyceraldehyde 3-phosphate to 1,3-
bisphosphoglycerate in a reaction which requires a phosphate ion and the redox cofactor 
NAD
+
 as reactants (scheme 1).  Therefore, it performs two functions:  it generates reduced 
cofactor (NADH) which can be reoxidised through oxidative phosphorylation under aerobic 
conditions and it produces the “high energy” molecule 1,3-bisphosphoglycerate.  This 
compound donates one of its phosphate groups to ADP in the subsequent reaction of the 
pathway resulting in the direct generation of ATP, a reaction which is critical for the 
organism’s survival under anaerobic conditions.  Thus it is likely that inhibition of GAPDH 
would result in reduced energy production and reduced growth of the organism.  Adenosine 
derivatives and 1,4-dihydro-4-oxoquinoline ribonucleosides which target the GAPDH of 
Trypanosoma spp have been shown to kill the organisms at micromolar concentrations 
[9;10].  Antitrypanosomal compounds which target GAPDH have also been isolated from 
Keetia leucantha leaves [11].  The antitumour compound 3-bromopyruvate targets human 
GAPDH resulting in altered energy metabolism and cell death [12-14]. 
 
The majority of GAPDH proteins which have been characterised are homotetrameric [15;16].  
However, there are some reports of dimeric and trimeric forms of the enzyme [17-19].  There 
is intra-molecular communication between the four active sites resulting in complex, 
cooperative ligand binding behaviour.  Saccharomyces cerevisiae GAPDH showed positively 
cooperative NAD
+
 binding (h=1.91) up to half-saturation of the active sites and mildly 
negative cooperativity (h=0.92) at higher concentrations of ligand [20].  The kinetic 
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mechanism of the enzyme requires the sequential addition of NAD
+
, glyceraldehyde 3-
phosphate and phosphate and the sequential release of 1,3-bisphosphoglycerate and NADH 
[21;22].  Following the binding of glyceraldehyde 3-phosphate to the enzyme, a cysteine 
residue (Cys-149 in the lobster enzyme) reacts with the substrate generating a covalent 
enzyme-substrate complex.  Oxidation by NAD
+
 then occurs in a reaction which requires a 
histidine residue to act as a base; the resulting NADH molecule is then exchanged for a new 
molecule of NAD
+
.  Inorganic phosphate reacts with, and displaces, the bound substrate 
generating 1,3-bisphosphoglycerate and regenerating the enzyme for a further round of 
catalysis [16;21;23]. 
 
There is also considerable evidence for GAPDH proteins having functions other than their 
catalytic role in glycolysis.  These functions include gene regulation, vesicle transport and the 
prevention of telomere shortening [24].  In some bacteria, for example, Bacillus anthracis 
and pathogenic strains of Escherichia coli, the protein is present on the extracellular surface 
and can interact with the mammalian plasma protein plasminogen [25;26].  Similar 
interactions occur between the extracellular GAPDH of the protozoan parasite Trichomonas 
vaginalis and plasminogen and fibronectin [27].  GAPDH is also released into the extra-
cellular environment by F. hepatica and by the blood flukes Schistosoma japonicum and 
Shistosoma mansoni [28-30].  In Schistosoma bovis, GAPDH is one of ten extracellular 
proteins which were identified as plasminogen binders [31].  It has been suggested that the 
plasminogen binding role of bacterial GAPDHs is important in pathogenesis [25].  This may 
also be the case in trematodes.  The extra-cellular location of the enzyme has resulted in 
trematode GAPDHs receiving considerable attention as a vaccine candidate [32-36].  
Vaccination with peptides derived from Schistosoma mansoni GAPDH conferred some 
protection on mice infected under laboratory conditions [32;34].  Immunisation of goats with 
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a DNA vaccine encoding Haemonchus contortus GAPDH resulted in partial protection 
against this parasite [37]. 
 
The development of novel drugs or vaccines for the treatment of F. hepatica infection will 
require a greater understanding of the biochemistry of this organism.  In light of the progress 
being made in the identification of antitrypanosomal and antitumour compounds which target 
this enzyme, we cloned, recombinantly expressed and biochemically characterised the 
GAPDH from F. hepatica (FhGAPDH). 
 
2.  Materials and Methods 
2.1 Cloning, expression and purification of FhGAPDH 
The coding sequence for FhGADH was amplified from F. hepatica cDNA by PCR.  The 
amplicon was inserted into the expression vector pET-46 Ek/LIC (Merck, Nottingham, UK) 
by ligation independent cloning according to the manufacturer’s protocol and the insert was 
sequenced (GATC Biotech, London). 
 
FhGAPDH was expressed in E. coli Rosetta(DE3) cells (Merck).  The expression vector was 
transformed into this strain and a single colony used to inoculate 100 ml of LB media 
(supplemented with 100 μgml-1 ampicillin and 34 μgml-1 chloramphenicol).  This culture was 
grown overnight, shaking at 30 ºC.  The following day, this was diluted into 1 l of LB 
(supplemented with 100 μgml-1 ampicillin and 34 μgml-1 chloramphenicol) and the culture 
grown, shaking at 30 ºC until A600nm=0.6-1.0 (typically ~5 h).  The culture was then induced 
with 0.2 g IPTG and grown at 16 ºC for 20-24 h.  Cells were harvested by centrifugation 
(4200g for 15 min), resuspended in ~20 ml of buffer R (50 mM Hepes-OH, pH 7.4, 150 mM 
NaCl, 10%(v/v) glycerol) and stored, frozen at -80 ºC.  The protein was purified from these 
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cells source using nickel-agarose resin (His-Select, Sigma, Poole, UK) as previously 
described for F. hepatica triose phosphate isomerase (FhTPI) [38]. 
 
2.2  Bioinformatics and molecular modelling 
The protein sequence of FhGAPDH was aligned to other, selected GAPDH sequences using 
ClustalW [39].  This alignment was used to construct a maximum likelihood tree using 
MEGA [40-42].  ProtParam from the EXPasY suite of programs was used to estimate the 
molecular mass and isoelectric point of the protein [43].  An initial molecular model of a 
FhGAPDH monomer was generated using Phyre2 [44].  Four of these monomeric structures 
were superimposed onto the subunits of human liver GAPDH (PDB:  1ZNQ [45]) using 
PyMol (www.pymol.org) to generate an initial model of tetrameric FhGAPDH.  This initial 
model was energy minimised using YASARA [46] to generate the final model which is 
provided as supplementary data to this paper. 
 
2.3  Analytical gel filtration 
FhGAPDH (250 μl of 120 μM solution) was resolved (flow rate 1 ml min-1) on a Sephacryl-
S300 (Sigma, Poole, UK) column of total volume (Vt) 49.5 ml in 50 mM TrisHCl, 17 mM 
Tris base, 150 mM sodium chloride, pH 7.4 [47].  The elution volume (Ve) was determined 
from the peak in absorbance at 280 nm.  The void volume (V0) was determined to be 17 ml 
by measuring the elution volume of blue dextran.  The column was calibrated by determining 
Ve for four standards (β-galactosidase, 116 kDa; BSA, 66 kDa; chymotrypsinogen A, 25 kDa; 
ribonuclease A, 14 kDa).  The partition constant (Kav) was calculated for these standards 
according to the equation Kav=(Vt-Ve)/(Vt-V0).  These values were used to construct a 
standard curve (Kav against the logarithm of the molecular mass) which was used, along with 
the Kav for FhGAPDH, to estimate that protein’s molecular mass. 
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2.4  Other analytical methods 
Protein concentrations were estimated using the method of Bradford [48] with BSA as a 
standard.  Protein-protein crosslinking with bissulfosuccinimidylsuberate (BS
3
) and the 
determination of protein melting points (Tm) by thermal scanning fluorimetry (TSF) were 
carried out as previously described [38;49]. 
 
2.5  Enzyme kinetics 
The rate of reaction catalysed by FhGAPDH was determined by measuring the increase in 
A340nm resulting from the reduction of NAD
+
 to NADH [50].  Reactions (150 μl) were 
monitored at 37 ºC in a Multiskan Spectrum spectrophotometric plate reader (Thermo 
Scientific) for 15 min and contained 1 mM NAD
+
, 30 mM sodium arsenate and 100 mM 
triethanolamine-HCl, pH 7.6.  They were initiated by the addition of FhGAPDH (12 nM, 
monomer).  Initial rates were estimated from the linear parts of the progress curves and 
plotted against substrate concentration.  These data were fitted to both the Michaelis-Menten 
and Hill equations by non-linear curve fitting as implemented in GraphPad Prism 5.0 
(GraphPad Software, CA, USA); an F-test was used to select the better fit. 
 
3 Results and Discussion 
3.1  A GAPDH from Fasciola hepatica 
The primary sequence of FhGAPDH (derived from the cDNA sequence, GenBank:  
KF700239) encodes a polypeptide of 338 amino acid residues, a calculated, monomeric 
molecular mass of 37 kDa and an estimated isoelectric point of 7.1.  Analysis of the protein 
sequence showed that FhGAPDH has greatest similarity to other trematode GAPDH enzymes 
and was well differentiated (bootstrap values >90) from GAPDH enzymes from potential 
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host species (Supplementary Figure 1).  The protein can be expressed in, and purified from, 
E. coli with a typical yield of ~4.5 mg per litre of bacterial culture (Figure 1a).  The 
recombinant protein was active and showed Michaelis-Menten kinetics with glyceraldehyde 
3-phosphate as a substrate (Figure 1b). 
 
3.2  FhGAPDH has a similar overall fold to mammalian GAPDHs 
The F. hepatica GAPDH protein sequence was used to model the three dimensional structure 
of the protein in a tetrameric form (Figure 2a).  Overall, the predicted fold and oligomeric 
arrangement was similar to that of the human enzyme (PDB:  1U8F [51]; rmsd 0.994 Å over 
8416 similar atoms).  The fold is also similar to that from other parasites, for example 
Plasmodium falciparum (PDB:  1YWG [52]; rmsd 1.226 Å over 8358 equivalent atoms) 
Trypanosoma brucei (PDB:  2X0N, [53]; rmsd 2.009 Å over 8522 equivalent atoms) and 
Trypanosoma cruzi (PDB:  4LSM, note that this structure only contains a dimer; rmsd 1.133 
Å over 4079 equivalent atoms).  Comparison to the structure of the human enzyme also 
enabled the prediction of the catalytically critical cysteine residue which reacts covalently in 
the reaction mechanism as Cys-152. 
 
A cleft in the protein, close to the 2’-OH on the NAD+, which is present in Trypanosoma spp 
GAPDH has been exploited in the structure based drug design of adenosine analogues.  This 
space is largely filled with the sidechain of Ile-37 in the human enzyme, thus leading to 
selectivity of these drugs for the parasite enzyme over the human one [54].  Ile-37 is 
conserved in the FhGAPDH (as Ile-38) and the backbone conformation in this region is 
similar to the human enzyme and not the T. brucei one (Figure 2b).  Therefore, this line of 
drug discovery is unlikely to be fruitful in F. hepatica. 
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3.3  The equilibrium between FhGAPDH tetramers and dimers is affected by ligands 
Addition of the crosslinker BS
3
 to FhGAPDH, followed by SDS-PAGE analysis resulted in 
the appearance of three additional bands at >120 kDa, ~70 kDa and ~80 kDa (Figure 3a).  
The highest molecular mass band is most likely a fully crosslinked tetramer and the two 
smaller bands may represent different conformations of dimers.  Interestingly, when 
glyceraldehyde 3-phosphate or NAD
+
 or the two substrates together were added, the largest 
band was not detected and the intensity of the ~70 kDa band increased relative to the ~80 
kDa one (Figure 3a).  The most likely explanation for this is that substrate binding induces 
conformational and oligomerisation changes in FhGAPDH. 
 
Analytical gel filtration of FhGAPDH in the absence of ligands resulted in a single peak at 
Ve=19 ml corresponding to an estimated molecular mass of 113 kDa, with a small “shoulder” 
at approximately 22 ml (70 kDa) (Figure 3b).  This is most consistent with a trimeric solution 
structure with some dimers also present although it should be noted that no trimers were 
detected by crosslinking (Figure 3a).  It is, therefore, possible that the major species detected 
by gel filtration is a tetramer with an unusually compact structure.  When this experiment was 
repeated using FhGAPDH mixed with NAD
+
 (9 μM), the estimated molecular mass dropped 
to 70 kDa (Ve=22 ml) (Figure 3b). 
 
Both methods provide evidence for a ligand-induced change in FhGAPDH’s conformation 
and oligomeric state.  Both glyceraldehyde 3-phosphate and NAD
+
 appear to favour the 
formation of dimers over tetramers.  Mammalian GAPDH’s oligomerisation states can also 
be affected by ligands.  Rabbit GAPDH dissociates into dimers in the presence of NAD
+
 and 
glyceraldehyde 3-phosphate; however, in contrast to FhGAPDH, both substrates are required 
[55].  In some mammalian species, addition of NAD
+
 alone stabilises the tetramer [56;57]. 
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3.4  FhGAPDH is greatly stabilised by substrates 
In the absence of ligands, FhGADH had a melting temperature of 46±1 ºC.  This is 
substantially lower than that measured for F. hepatica triose phosphate isomerase (67.0 ºC) 
under similar conditions [38].  The value is also lower than those for rabbit GAPDH (54.7 ºC, 
determined by turbidity measurements) [58;59].  Addition of glyceraldehyde 3-phosphate or 
NAD
+
 increased the melting temperature in a saturatable, concentration-dependent manner 
(Figure 4).  In previous studies on liver fluke and human enzymes using this technique 
ligand-induced stabilisation typically increased the melting temperature by 2-5 K [38;49;60].  
However both FhGAPDH substrates caused changes in Tm of more than 20 K (Figure 4).  
The effect of glyceraldehyde 3-phosphate fit well to a simple, one site binding curve 
(KD,app=4.2±0.4 mM).  However, the data obtained with NAD
+
 fitted better to a cooperative 
binding curve, with a Hill coefficient (h) of 0.48±0.02 and a KD,app of 0.67±0.16 mM.  Since 
the effects of substrate on thermal denaturation are complex, there is a risk of over-
interpretation of these findings.  However, these results suggest that the binding of the two 
substrates has different effects on the protein and that NAD
+
 may bind in a negatively 
cooperative manner. 
 
3.5  Dynamic behaviour of the oligomeric forms of FhGAPDH 
Taken together, data from oligomerisation and stability experiments suggest the following 
model for FhGAPDH’s behaviour.  In the absence of substrates, the enzyme exists as an 
equilibrium mixture of tetramers and two forms of dimer.  Either glyceraldehyde 3-phosphate 
or NAD
+
 shifts this equilibrium towards one of the two dimer forms (Figure 3).  This form is 
substantially more resistant to thermal denaturation than either the other dimeric form or the 
tetramer (Figure 4).  By analogy with GAPDHs from other species, which often adopt more 
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compact forms on binding ligands, we hypothesise that this more stable form is also a more 
compact one.  This hypothesis is consistent with the faster migration of its corresponding 
crosslinked product in SDS-PAGE (Figure 3a). 
 
3.6 Conclusions and future prospects 
FhGAPDH has a similar sequence and predicted three-dimensional structure to mammalian 
GAPDHs (Figures S1, 2a).  It lacks a key binding cleft which has been exploited in the 
design of anti-parasitic drugs targeting GAPDH enzymes from unicellular parasites (Figure 
2b).  However, FhGAPDH does show an important biochemical difference when compared to 
mammalian GAPDH:  its tetramer-dimer equilibrium responds differently to ligands.  Further 
understanding of this process by, for example, molecular dynamics simulations may suggest 
ways to perturb this equilibrium.  It would also be desirable to determine if FhGAPDH, like 
GAPDHs from other species, has functions other than its catalytic role in glycolysis.  
Understanding these roles may also suggest possible avenues for therapeutically relevant 
disruption or vaccine development. 
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Figure legends 
Figure 1:  Expression, purification and activity of FhGAPDH.  (a) Expression and 
purification of FhGAPDH was monitored by 10% SDS-PAGE.  The purified protein is 
indicated by an arrow to the right of the gel.  M, molecular mass markers (masses to the left 
of the gel in kDa); U, total protein extract from uninduced E. coli cells just prior to induction; 
I, total protein extract from E. coli cells 2 h after induction; S, soluble proteins released on 
sonication and after centrifugation to remove solid matter; W1, material which passed through 
the column following application of the sonicate; W2, material washed from the column by 
washing in buffer A (50 mM Hepes-OH, pH 7.4, 500 mM NaCl, 10%(v/v) glycerol); E1, E2 
and E3 three times 2 ml elutions in buffer B (buffer A supplemented with 250 mM 
imidazole).  (b) Activity of FhGAPDH was monitored by measuring the rate of production of 
NADH (see Materials and Methods) as a function of glyceraldehyde 3-phosphate 
concentration.  The data were fitted to the Michaelis-Menten equation with an apparent 
Michaelis constant (Km,app) of 1.01±0.15 mM and an apparent maximum rate (Vmax,app) of 
0.044±0.002 μMs-1.  Each point represents the mean of three independent determinations of 
the rate and the error bars the standard errors of these means.  The line is a non-linear fit to 
the Michaelis-Menten equation. 
 
Figure 2:  Predicted structure of FhGAPDH.  (a)  The overall fold of FhGAPDH was 
modelled as a tetramer by analogy to other GAPDH enzymes (described in Materials and 
Methods).  The quaternary structure is shown as a “dimer of dimers” arrangement.  The 
figure was produced using PyMol and each polypeptide chain of the tetramer is shown in a 
different colour.  (b) A close up of the structure near the binding pocket which has been 
exploited in the design of novel anti-trypanosomal drugs.  FhGAPDH (lime green; residues 
Val-33 to Met-43) and human GAPDH (blue; residues Phe-33 to Met-43) show high similar 
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folds in this region, whereas T. brucei GAPDH (pink; residues Val-35 to Phe-45) has a 
different backbone conformation creating a binding pocket close to the hydroxyl groups on 
the ribose of NAD
+
.  An NAD
+
 molecule from T. brucei GAPDH is also shown. 
 
Figure 3:  Oligomerisation of FhGAPDH.  (a) Crosslinking of FhGAPDH (30 μM) with 
BS
3
 (800 μM) revealed ligand-induced changes in the oligomeric state.  Proteins were 
incubated with ligands (5 mM) as shown for 15 min at 37 ºC prior to the addition of 
crosslinker.  After 30 min of reaction, the products were analysed by 8% SDS-PAGE.  The 
first lane contains molecular mass markers (masses to the left of the gel in kDa) and the 
second FhGAPDH in the absence of ligands or crosslinker.  (b)  Analytical gel filtration of 
FhGAPDH (250 μl of 122 μM) showed a different elution profile in the presence and absence 
of NAD
+
 (9 μM).  A calibration curve (inset) was constructed using proteins of known 
molecular mass and used to estimate the molecular mass of FhGAPDH.  That the major peaks 
contained FhGAPDH was verified by SDS-PAGE (data not shown). 
 
Figure 4:  Thermal stability of FhGAPDH.  The effect of varying the concentrations of 
substrates on the melting temperature of FhGAPDH (3 μM) was measured.  Each point 
represents the mean of three independent determinations of the rate and the error bars the 
standard errors of these means.  The lines are non-linear fits to simple, one site binding 
(glyceraldehyde 3-phosphate, upper panel) and negatively cooperative binding (NAD
+
, lower 
panel). 
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Abstract 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) catalyses one of the two steps in 
glycolysis which generate the reduced coenzyme NADH.  This reaction precedes the two 
ATP generating steps.  Thus, inhibition of GAPDH will lead to substantially reduced energy 
generation.  Consequently, there has been considerable interest in developing GAPDH 
inhibitors as anti-cancer and anti-parasitic agents.  Here, we describe the biochemical 
characterisation of GAPDH from the common liver fluke Fasciola hepatica (FhGAPDH).  
The primary sequence of FhGAPDH is similar to that from other trematodes and the 
predicted structure shows high similarity to those from other animals including the 
mammalian hosts.  FhGAPDH lacks a binding pocket which has been exploited in the design 
of novel antitrypanosomal compounds.  The protein can be expressed in, and purified from 
Escherichia coli; the recombinant protein was active and showed no cooperativity towards 
glyceraldehyde 3-phosphate as a substrate.  In the absence of ligands, FhGAPDH was a 
mixture of homodimers and tetramers, as judged by protein-protein crosslinking and 
analytical gel filtration.  The addition of either NAD
+
 or glyceraldehyde 3-phosphate shifted 
this equilibrium towards a compact dimer.  Thermal scanning fluorimetry demonstrated that 
this form was considerably more stable than the unliganded one.  These responses to ligand 
binding differ from those seen in mammalian enzymes.  These differences could be exploited 
in the discovery of reagents which selectively disrupt the function of FhGAPDH. 
 
Keywords:  glycolytic enzyme; trematode; drug target; vaccine target; neglected tropical 
disease; G3PDH 
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1. Introduction 
In recent years, there has been renewed interest in targeting metabolic enzymes in the 
treatment of infectious diseases [1].  This presents considerable challenges – most 
significantly the highly conserved nature of these proteins which makes the discovery of 
reagents which discriminate between host and pathogen enzymes difficult.  However, the 
essential nature of pathways such as glycolysis mean that inhibition is likely to lead to growth 
inhibition and subsequent death of the pathogen.  Thus, increased efforts are being made to 
characterise the biochemistry of metabolic enzymes from pathogens with the long term aim 
of investigating their potential as drug targets.  A key goal of these studies is to identify 
biochemical differences between the pathogen enzyme and the host enzyme.  These 
differences may then provide the basis for the discovery of compounds which selectively 
disrupt the activity of the pathogen enzyme. 
 
Fasciola hepatica (the common liver fluke) is a trematode which infects humans and other 
mammals.  It is estimated that approximately 7 million humans are infected with millions 
more at risk; the majority of these people live in the developing world and fascioliasis is 
classified as a neglected tropical disease by WHO [2].  In addition, the organism causes a 
significant economic burden to agriculture globally since it infects domestic herbivores such 
as cows and sheep.  Over ten years ago global losses due to infection were estimated to be 
several billion US dollars [3].  F. hepatica infections can be treated with the modified 
benzimidazole drug triclabendazole.  This compound is highly effective and kills both mature 
and juvenile worms.  However, resistance to this drug is emerging worldwide and resistance 
to alternative benzimidazoles such as albendazole has also been reported [4-6].  It is 
inevitable that triclabendazole resistance will spread and the agricultural burden of F. 
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hepatica infections is likely to increase if the trend to warmer, wetter summers in temperate 
regions continues [7;8]. 
 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH; EC 1.2.1.12) is a key enzyme in the 
glycolytic pathway.  It catalyses the oxidation of glyceraldehyde 3-phosphate to 1,3-
bisphosphoglycerate in a reaction which requires a phosphate ion and the redox cofactor 
NAD
+
 as reactants (scheme 1).  Therefore, it performs two functions:  it generates reduced 
cofactor (NADH) which can be reoxidised through oxidative phosphorylation under aerobic 
conditions and it produces the “high energy” molecule 1,3-bisphosphoglycerate.  This 
compound donates one of its phosphate groups to ADP in the subsequent reaction of the 
pathway resulting in the direct generation of ATP, a reaction which is critical for the 
organism’s survival under anaerobic conditions.  Thus it is likely that inhibition of GAPDH 
would result in reduced energy production and reduced growth of the organism.  Adenosine 
derivatives and 1,4-dihydro-4-oxoquinoline ribonucleosides which target the GAPDH of 
Trypanosoma spp have been shown to kill the organisms at micromolar concentrations 
[9;10].  Antitrypanosomal compounds which target GAPDH have also been isolated from 
Keetia leucantha leaves [11].  The antitumour compound 3-bromopyruvate targets human 
GAPDH resulting in altered energy metabolism and cell death [12-14]. 
 
The majority of GAPDH proteins which have been characterised are homotetrameric [15;16].  
However, there are some reports of dimeric and trimeric forms of the enzyme [17-19].  There 
is intra-molecular communication between the four active sites resulting in complex, 
cooperative ligand binding behaviour.  Saccharomyces cerevisiae GAPDH showed positively 
cooperative NAD
+
 binding (h=1.91) up to half-saturation of the active sites and mildly 
negative cooperativity (h=0.92) at higher concentrations of ligand [20].  The kinetic 
5 
 
mechanism of the enzyme requires the sequential addition of NAD
+
, glyceraldehyde 3-
phosphate and phosphate and the sequential release of 1,3-bisphosphoglycerate and NADH 
[21;22].  Following the binding of glyceraldehyde 3-phosphate to the enzyme, a cysteine 
residue (Cys-149 in the lobster enzyme) reacts with the substrate generating a covalent 
enzyme-substrate complex.  Oxidation by NAD
+
 then occurs in a reaction which requires a 
histidine residue to act as a base; the resulting NADH molecule is then exchanged for a new 
molecule of NAD
+
.  Inorganic phosphate reacts with, and displaces, the bound substrate 
generating 1,3-bisphosphoglycerate and regenerating the enzyme for a further round of 
catalysis [16;21;23]. 
 
There is also considerable evidence for GAPDH proteins having functions other than their 
catalytic role in glycolysis.  These functions include gene regulation, vesicle transport and the 
prevention of telomere shortening [24].  In some bacteria, for example, Bacillus anthracis 
and pathogenic strains of Escherichia coli, the protein is present on the extracellular surface 
and can interact with the mammalian plasma protein plasminogen [25;26].  Similar 
interactions occur between the extracellular GAPDH of the protozoan parasite Trichomonas 
vaginalis and plasminogen and fibronectin [27].  GAPDH is also released into the extra-
cellular environment by F. hepatica and by the blood flukes Schistosoma japonicum and 
Schistosoma mansoni [28-30].  In Schistosoma bovis, GAPDH is one of ten extracellular 
proteins which were identified as plasminogen binders [31].  It has been suggested that the 
plasminogen binding role of bacterial GAPDHs is important in pathogenesis [25].  This may 
also be the case in trematodes.  The extra-cellular location of the enzyme has resulted in 
trematode GAPDHs receiving considerable attention as vaccine candidates [32-36].  
Vaccination with peptides derived from Schistosoma mansoni GAPDH conferred some 
protection on mice infected under laboratory conditions [32;34].  Immunisation of goats with 
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a DNA vaccine encoding Haemonchus contortus GAPDH resulted in partial protection 
against this parasite [37]. 
 
The development of novel drugs or vaccines for the treatment of F. hepatica infection will 
require a greater understanding of the biochemistry of this organism.  In light of the progress 
being made in the identification of antitrypanosomal and antitumour compounds which target 
this enzyme, we cloned, recombinantly expressed and biochemically characterised the 
GAPDH from F. hepatica (FhGAPDH). 
 
2.  Materials and Methods 
2.1 Cloning, expression and purification of FhGAPDH 
The coding sequence for FhGADH was amplified from F. hepatica cDNA by PCR using 
primers:  5'-GACGACGACAAGATGTCCAAACCCAAAGTG-3' (forward) and 5'-
GAGGAGAAGCCCGGTTCACAATACCTTTTGCTTCCA-3' (reverse).  The amplicon was 
inserted into the expression vector pET-46 Ek/LIC (Merck, Nottingham, UK) by ligation 
independent cloning according to the manufacturer’s protocol.  This method uses the proof-
reading activity of T4 DNA polymerase to generate long overhangs at the 5 -ʹ and 3 -ʹends 
of the insert, thus avoiding the need for restriction digestion and ligation.  The vector adds 
sequence coding for an N-terminal hexahistidine tag (MAHHHHHHVDDDDK).  The 
presence of the insert was verified by PCR and then the insert was sequenced (GATC 
Biotech, London). 
 
FhGAPDH was expressed in E. coli Rosetta(DE3) cells (Merck).  The expression vector was 
transformed into this strain and a single colony used to inoculate 100 ml of LB media 
(supplemented with 100 μgml-1 ampicillin and 34 μgml-1 chloramphenicol).  This culture was 
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grown overnight, shaking at 30 ºC.  The following day, this was diluted into 1 l of LB 
(supplemented with 100 μgml-1 ampicillin and 34 μgml-1 chloramphenicol) and the culture 
grown, shaking at 30 ºC until A600nm=0.6-1.0 (typically ~5 h).  The culture was then induced 
with 0.2 g IPTG and grown at 16 ºC for 20-24 h.  Cells were harvested by centrifugation 
(4200g for 15 min), resuspended in ~20 ml of buffer R (50 mM Hepes-OH, pH 7.4, 150 mM 
NaCl, 10%(v/v) glycerol) and stored, frozen at -80 ºC.  The protein was purified from these 
cells source using nickel-agarose resin (His-Select, Sigma, Poole, UK) as previously 
described for F. hepatica triose phosphate isomerase (FhTPI) [38]. 
 
2.2  Bioinformatics and molecular modelling 
The protein sequence of FhGAPDH was aligned to other, selected GAPDH sequences using 
ClustalW [39].  This alignment was used to construct a maximum likelihood tree using 
MEGA [40-42].  ProtParam from the EXPasY suite of programs was used to estimate the 
molecular mass and isoelectric point of the protein [43].  An initial molecular model of a 
FhGAPDH monomer was generated using Phyre2 [44].  Four of these monomeric structures 
were superimposed onto the subunits of human liver GAPDH (PDB:  1ZNQ [45]) using 
PyMol (www.pymol.org) to generate an initial model of tetrameric FhGAPDH.  This initial 
model was energy minimised using YASARA [46] to generate the final model which is 
provided as supplementary data to this paper. 
 
2.3  Analytical gel filtration 
FhGAPDH (250 μl of 120 μM solution) was resolved (flow rate 1 ml min-1) on a Sephacryl-
S300 (Sigma, Poole, UK) column of total volume (Vt) 49.5 ml in 50 mM TrisHCl, 17 mM 
Tris base, 150 mM sodium chloride, pH 7.4 [47].  The elution volume (Ve) was determined 
from the peak in absorbance at 280 nm.  The void volume (V0) was determined to be 17 ml 
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by measuring the elution volume of blue dextran.  The column was calibrated by determining 
Ve for four standards (β-galactosidase, 116 kDa; BSA, 66 kDa; chymotrypsinogen A, 25 kDa; 
ribonuclease A, 14 kDa).  The partition constant (Kav) was calculated for these standards 
according to the equation Kav=(Vt-Ve)/(Vt-V0).  These values were used to construct a 
standard curve (Kav against the logarithm of the molecular mass) which was used, along with 
the Kav for FhGAPDH, to estimate that protein’s molecular mass. 
 
2.4  Other analytical methods 
Protein concentrations were estimated using the method of Bradford [48] with BSA as a 
standard.  Protein-protein crosslinking with bissulfosuccinimidylsuberate (BS
3
) and the 
determination of protein melting points (Tm) by thermal scanning fluorimetry (TSF) were 
carried out as previously described [38;49]. 
 
2.5  Enzyme kinetics 
The rate of reaction catalysed by FhGAPDH was determined by measuring the increase in 
A340nm resulting from the reduction of NAD
+
 to NADH [50].  Reactions (150 μl) were 
monitored at 37 ºC in a Multiskan Spectrum spectrophotometric plate reader (Thermo 
Scientific) for 15 min and contained 1 mM NAD
+
, 30 mM sodium arsenate and 100 mM 
triethanolamine-HCl, pH 7.6.  They were initiated by the addition of FhGAPDH (12 nM, 
monomer).  Initial rates were estimated from the linear parts of the progress curves and 
plotted against substrate concentration.  These data were fitted to both the Michaelis-Menten 
and Hill equations by non-linear curve fitting as implemented in GraphPad Prism 5.0 
(GraphPad Software, CA, USA); an F-test was used to select the better fit. 
 
3 Results and Discussion 
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3.1  A GAPDH from Fasciola hepatica 
The primary sequence of FhGAPDH (derived from the cDNA sequence, GenBank:  
KF700239) encodes a polypeptide of 338 amino acid residues, a calculated, monomeric 
molecular mass of 37 kDa and an estimated isoelectric point of 7.1.  Analysis of the protein 
sequence showed that FhGAPDH has greatest similarity to other trematode GAPDH enzymes 
and was well differentiated (bootstrap values >90) from GAPDH enzymes from potential 
host species (Supplementary Figure 1).  The protein can be expressed in, and purified from, 
E. coli with a typical yield of ~4.5 mg per litre of bacterial culture (Figure 1a).  The 
recombinant protein was active and showed Michaelis-Menten kinetics with glyceraldehyde 
3-phosphate as a substrate (Figure 1b). 
 
3.2  FhGAPDH has a similar overall fold to mammalian GAPDHs 
The F. hepatica GAPDH protein sequence was used to model the three dimensional structure 
of the protein in a tetrameric form (Figure 2a).  Overall, the predicted fold and oligomeric 
arrangement was similar to that of the human enzyme (PDB:  1U8F [51]; rmsd 0.994 Å over 
8416 similar atoms).  The fold is also similar to that from other parasites, for example 
Plasmodium falciparum (PDB:  1YWG [52]; rmsd 1.226 Å over 8358 equivalent atoms) 
Trypanosoma brucei (PDB:  2X0N, [53]; rmsd 2.009 Å over 8522 equivalent atoms) and 
Trypanosoma cruzi (PDB:  4LSM, note that this structure only contains a dimer; rmsd 1.133 
Å over 4079 equivalent atoms).  Comparison to the structure of the human enzyme also 
enabled the prediction of the catalytically critical cysteine residue which reacts covalently in 
the reaction mechanism as Cys-152. 
 
A cleft in the protein, close to the 2’-OH on the NAD+, which is present in Trypanosoma spp 
GAPDH has been exploited in the structure based drug design of adenosine analogues.  This 
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space is largely filled with the sidechain of Ile-37 in the human enzyme, thus leading to 
selectivity of these drugs for the parasite enzyme over the human one [54].  Ile-37 is 
conserved in the FhGAPDH (as Ile-38) and the backbone conformation in this region is 
similar to the human enzyme and not the T. brucei one (Figure 2b).  Therefore, this line of 
drug discovery is unlikely to be fruitful in F. hepatica. 
 
3.3  The equilibrium between FhGAPDH tetramers and dimers is affected by ligands 
Addition of the crosslinker BS
3
 to FhGAPDH, followed by SDS-PAGE analysis resulted in 
the appearance of three additional bands at >120 kDa, ~70 kDa and ~80 kDa (Figure 3a).  
The highest molecular mass band is most likely a fully crosslinked tetramer.  The two smaller 
bands correspond to molecular masses close to that predicted for a dimer (74 kDa).  It is 
possible that these represent two different conformations, one more open (and thus more 
slowly migrating) and one more compact (see also Section 3.5).  Interestingly, when 
glyceraldehyde 3-phosphate, NAD
+
 or the two substrates together were added, the largest 
band was not detected and the intensity of the ~70 kDa band increased relative to the ~80 
kDa one (Figure 3a).  The most likely explanation for this is that substrate binding induces 
conformational and oligomerisation changes in FhGAPDH. 
 
Analytical gel filtration of FhGAPDH in the absence of ligands resulted in a single peak at 
Ve=19 ml corresponding to an estimated molecular mass of 113 kDa, with a small “shoulder” 
at approximately 22 ml (70 kDa) (Figure 3b).  This is most consistent with a trimeric solution 
structure with some dimers also present although it should be noted that no trimers were 
detected by crosslinking (Figure 3a).  It is, therefore, possible that the major species detected 
by gel filtration under these conditions is a tetramer with an unusually compact structure.  
When this experiment was repeated using FhGAPDH mixed with NAD
+
 (9 μM), the 
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estimated molecular mass dropped to 70 kDa (Ve=22 ml) (Figure 3b).  Under these conditions 
two additional peaks were observed, a small one corresponding to an approximate molecular 
mass of 7 kDa (Ve=30 ml) which we assumed to result from degradation and a broad peak 
(Ve approximately 41 ml) which corresponded to unbound NAD
+
 (Figure 3b). 
 
Both methods provide evidence for a ligand-induced change in FhGAPDH’s conformation 
and oligomeric state.  Both glyceraldehyde 3-phosphate and NAD
+
 appear to favour the 
formation of dimers over tetramers.  Mammalian GAPDH’s oligomerisation states can also 
be affected by ligands.  Rabbit GAPDH dissociates into dimers in the presence of NAD
+
 and 
glyceraldehyde 3-phosphate; however, in contrast to FhGAPDH, both substrates are required 
[55].  In some mammalian species, addition of NAD
+
 alone stabilises the tetramer [56;57]. 
 
3.4  FhGAPDH is greatly stabilised by substrates 
In the absence of ligands, FhGADH had a melting temperature of 46±1 ºC.  This is 
substantially lower than that measured for F. hepatica triose phosphate isomerase (67.0 ºC) 
under similar conditions [38].  The value is also lower than those for rabbit GAPDH (54.7 ºC, 
determined by turbidity measurements) [58;59].  Addition of glyceraldehyde 3-phosphate or 
NAD
+
 increased the melting temperature in a saturatable, concentration-dependent manner 
(Figure 4).  In previous studies on liver fluke and human enzymes using this technique 
ligand-induced stabilisation typically increased the melting temperature by 2-5 K [38;49;60].  
However both FhGAPDH substrates caused changes in Tm of more than 20 K (Figure 4).  
The effect of glyceraldehyde 3-phosphate fitted well to a simple, one site binding curve 
(KD,app=4.2±0.4 mM).  However, the data obtained with NAD
+
 fitted better to a cooperative 
binding curve, with a Hill coefficient (h) of 0.48±0.02 and a KD,app of 0.67±0.16 mM.  Since 
the effects of substrate on thermal denaturation are complex, there is a risk of over-
12 
 
interpretation of these findings.  However, these results suggest that the binding of the two 
substrates has different effects on the protein and that NAD
+
 may bind in a negatively 
cooperative manner. 
 
3.5  Dynamic behaviour of the oligomeric forms of FhGAPDH 
Taken together, data from oligomerisation and stability experiments suggest the following 
model for FhGAPDH’s behaviour.  In the absence of substrates, the enzyme exists as an 
equilibrium mixture of tetramers and two forms of dimer.  Addition of either glyceraldehyde 
3-phosphate or NAD
+
 shifts this equilibrium towards one of the two dimer forms (Figure 3).  
This form is substantially more resistant to thermal denaturation than either the other dimeric 
form or the tetramer (Figure 4).  By analogy with GAPDHs from other species, which often 
adopt more compact forms on binding ligands (see, for example, [17]), we hypothesise that 
this more stable form is also a more compact one.  This hypothesis is consistent with the 
faster migration of its corresponding crosslinked product in SDS-PAGE (Figure 3a). 
 
3.6 Conclusions and future prospects 
FhGAPDH has a similar sequence and predicted three-dimensional structure to mammalian 
GAPDHs (Figures S1, 2a).  It lacks a key binding cleft which has been exploited in the 
design of anti-parasitic drugs targeting GAPDH enzymes from unicellular parasites (Figure 
2b).  However, FhGAPDH does show an important biochemical difference when compared to 
mammalian GAPDH:  its tetramer-dimer equilibrium responds differently to ligands.  Further 
understanding of this process by, for example, molecular dynamics simulations may suggest 
ways to perturb this equilibrium.  It would also be desirable to determine if FhGAPDH, like 
GAPDHs from other species, has functions other than its catalytic role in glycolysis.  We 
postulate that these roles could be similar to those seen in some bacterial pathogens and other 
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parasites, i.e interaction with plasma proteins during pathogenesis [25-27].  By analogy to 
higher eukaryotes, it may also have cell signalling roles in F. hepatica [24]. Understanding 
these various roles may also suggest possible avenues for therapeutically relevant disruption 
or vaccine development. 
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Figure legends 
Figure 1:  Expression, purification and activity of FhGAPDH.  (a) Expression and 
purification of FhGAPDH was monitored by 10% SDS-PAGE.  The purified protein is 
indicated by an arrow to the right of the gel.  M, molecular mass markers (masses to the left 
of the gel in kDa); U, total protein extract from uninduced E. coli cells just prior to induction; 
I, total protein extract from E. coli cells 2 h after induction; S, soluble proteins released on 
sonication and after centrifugation to remove solid matter; W1, material which passed through 
the nickel agarose column following application of the sonicate; W2, material washed from 
the column by washing in buffer A (50 mM Hepes-OH, pH 7.4, 500 mM NaCl, 10%(v/v) 
glycerol); E1, E2 and E3 three times 2 ml elutions in buffer B (buffer A supplemented with 
250 mM imidazole).  (b) Activity of FhGAPDH was monitored by measuring the rate of 
production of NADH (see Materials and Methods) as a function of glyceraldehyde 3-
phosphate concentration.  The data were fitted to the Michaelis-Menten equation with an 
apparent Michaelis constant (Km,app) of 1.01±0.15 mM and an apparent maximum rate 
(Vmax,app) of 0.044±0.002 μMs
-1
.  Each point represents the mean of three independent 
determinations of the rate and the error bars the standard errors of these means.  The line is a 
non-linear fit to the Michaelis-Menten equation. 
 
Figure 2:  Predicted structure of FhGAPDH.  (a)  The overall fold of FhGAPDH was 
modelled as a tetramer by analogy to other GAPDH enzymes (described in Materials and 
Methods).  The quaternary structure is shown as a “dimer of dimers” arrangement.  The 
figure was produced using PyMol and each polypeptide chain of the tetramer is shown in a 
different colour.  (b) A close up of the structure near the binding pocket which has been 
exploited in the design of novel anti-trypanosomal drugs.  FhGAPDH (lime green; residues 
Val-33 to Met-43) and human GAPDH (blue; residues Phe-33 to Met-43) show high similar 
23 
 
folds in this region, whereas T. brucei GAPDH (pink; residues Val-35 to Phe-45) has a 
different backbone conformation creating a binding pocket close to the hydroxyl groups on 
the ribose of NAD
+
.  An NAD
+
 molecule from T. brucei GAPDH is also shown. 
 
Figure 3:  Oligomerisation of FhGAPDH.  (a) Crosslinking of FhGAPDH (30 μM) with 
BS
3
 (800 μM) revealed ligand-induced changes in the oligomeric state.  Proteins were 
incubated with ligands (5 mM) as shown for 15 min at 37 ºC prior to the addition of 
crosslinker.  After 30 min of reaction, the products were analysed by 8% SDS-PAGE.  The 
first lane contains molecular mass markers (masses to the left of the gel in kDa) and the 
second FhGAPDH in the absence of ligands or crosslinker.  (b)  Analytical gel filtration of 
FhGAPDH (250 μl of 122 μM) showed a different elution profile in the presence and absence 
of NAD
+
 (9 μM).  A calibration curve (inset) was constructed using proteins of known 
molecular mass and used to estimate the molecular mass of FhGAPDH.  That the major peaks 
contained FhGAPDH was verified by SDS-PAGE (data not shown). 
 
Figure 4:  Thermal stability of FhGAPDH.  The effect of varying the concentrations of 
substrates on the melting temperature of FhGAPDH (3 μM) was measured.  Each point 
represents the mean of three independent determinations and the error bars the standard errors 
of these means.  The lines are non-linear fits to simple, one site binding (glyceraldehyde 3-
phosphate, upper panel) and negatively cooperative binding (NAD
+
, lower panel). 
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 Supplementary Figure S1:  Maximum Likelihood tree showing similarity in GAPDH protein sequences from 
selected organisms. 
The tree was calculated using the Maximum Likelihood method based on the JTT matrix-based model [S1]. The 
tree with the highest log likelihood (-6149.4229) is shown. The percentage of trees in which the associated 
taxa clustered together is shown next to the branches (5000 bootstraps). Initial tree(s) for the heuristic search 
were obtained automatically by applying Neighbour-Join and BioNJ algorithms to a matrix of pairwise 
distances estimated using a JTT model, and then selecting the topology with superior log likelihood value. The 
tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis 
involved 19 amino acid sequences. All positions containing gaps and missing data were eliminated. There were 
a total of 330 positions in the final dataset. Evolutionary analyses were conducted in MEGA5 [S2]. 
Species abbreviations:  Fh, Fasciola hepatica; Hs, Homo sapiens; Bt, Bos Taurus; Ss, Sos scrofa; La, Loxodonta 
Africana; Gg, Gallus gallus; Dm, Drosophila melanogaster; Ha, Homarus americanus; Sb, Schistosoma bovis; 
Sm, Schistosoma mansoni; Cs, Clonorchis sinensis; Ce, Caenorhabditis elegans; Hc, Haemonchus contortus; Bm, 
Brugia malayi; Ts, Taenia solium; Tb, Trypanosoma brucei; Pf, Plasmodium falciparum; Eh, Entamoeba 
histolytica; Sc, Saccharomyces cerevisiae. 
S1. Jones D.T., Taylor W.R., and Thornton J.M. (1992). The rapid generation of mutation data matrices from 
protein sequences. Computer Applications in the Biosciences 8: 275-282. 
S2. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., and Kumar S. (2011). MEGA5: Molecular 
Evolutionary Genetics Analysis using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony 
Methods. Molecular Biology and Evolution 28: 2731-2739. 
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3D molecular models ( PDB, PSE or MOL/MOL2)
Click here to download 3D molecular models ( PDB, PSE or MOL/MOL2): FhGAPDH_4mer_mini.pdb
